MedTrace Logo

The SUMMIT Study: A Cancer Screening Study

NCT03934866 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 13035

Last updated 2024-12-05

No results posted yet for this study

Summary

The SUMMIT Study will enrol 13,000 participants in order to investigate how cancer screening can be improved and delivered. The SUMMIT Study has two main aims: the first is to clinically validate a blood test for detecting multiple cancers at an early stage. The second is to examine the feasibility of delivering a low-dose CT (LDCT) screening service for lung cancer to a high-risk population in North Central and East London.

Conditions

Interventions

RADIATION

Low Dose CT scan

Low Dose chest CT scan conferring an equivalent radiation dose of less than 2 mSv to the average size patient. The study aims to keep most scans under 1 mSv (ultra-low dose), and all scans under 2 mSv.

Sponsors & Collaborators

  • GRAIL, Inc.

    collaborator INDUSTRY

  • University College London Hospitals

    collaborator OTHER

  • University College, London

    lead OTHER

Eligibility

Min Age
55 Years
Max Age
77 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-08
Primary Completion
2025-05-31
Completion
2030-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03934866 on ClinicalTrials.gov